Alec Stranahan
Stock Analyst at B of A Securities
(0.50)
# 4,163
Out of 5,180 analysts
34
Total ratings
32%
Success rate
-60.74%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Alec Stranahan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WVE Wave Life Sciences | Maintains: Buy | $38 → $21 | $6.62 | +217.22% | 1 | Mar 27, 2026 | |
| KRYS Krystal Biotech | Maintains: Buy | $288 → $318 | $246.94 | +28.78% | 6 | Jan 22, 2026 | |
| CADL Candel Therapeutics | Downgrades: Neutral | $13 → $7 | $4.48 | +56.25% | 2 | Sep 3, 2025 | |
| XNCR Xencor | Downgrades: Neutral | $23 → $12 | $11.35 | +5.73% | 2 | Sep 3, 2025 | |
| ERAS Erasca | Downgrades: Underperform | $4 → $1 | $14.94 | -93.31% | 3 | Sep 3, 2025 | |
| NVAX Novavax | Downgrades: Underperform | $9 → $7 | $8.09 | -13.47% | 5 | Aug 20, 2025 | |
| BEAM Beam Therapeutics | Upgrades: Buy | $42 | $21.90 | +91.78% | 1 | Mar 28, 2025 | |
| DAWN Day One Biopharmaceuticals | Maintains: Buy | $28 → $25 | $21.42 | +16.71% | 5 | Jan 7, 2025 | |
| CRBU Caribou Biosciences | Maintains: Buy | $13 → $11 | $1.72 | +539.53% | 1 | Jan 7, 2025 | |
| CATX Perspective Therapeutics | Downgrades: Neutral | $24 → $6 | $3.83 | +56.66% | 2 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $13 → $15 | $2.23 | +572.65% | 1 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $55 | $92.71 | -40.68% | 3 | Jul 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $5 → $6 | $31.51 | -80.96% | 2 | Dec 29, 2022 |
Wave Life Sciences
Mar 27, 2026
Maintains: Buy
Price Target: $38 → $21
Current: $6.62
Upside: +217.22%
Krystal Biotech
Jan 22, 2026
Maintains: Buy
Price Target: $288 → $318
Current: $246.94
Upside: +28.78%
Candel Therapeutics
Sep 3, 2025
Downgrades: Neutral
Price Target: $13 → $7
Current: $4.48
Upside: +56.25%
Xencor
Sep 3, 2025
Downgrades: Neutral
Price Target: $23 → $12
Current: $11.35
Upside: +5.73%
Erasca
Sep 3, 2025
Downgrades: Underperform
Price Target: $4 → $1
Current: $14.94
Upside: -93.31%
Novavax
Aug 20, 2025
Downgrades: Underperform
Price Target: $9 → $7
Current: $8.09
Upside: -13.47%
Beam Therapeutics
Mar 28, 2025
Upgrades: Buy
Price Target: $42
Current: $21.90
Upside: +91.78%
Day One Biopharmaceuticals
Jan 7, 2025
Maintains: Buy
Price Target: $28 → $25
Current: $21.42
Upside: +16.71%
Caribou Biosciences
Jan 7, 2025
Maintains: Buy
Price Target: $13 → $11
Current: $1.72
Upside: +539.53%
Perspective Therapeutics
Nov 25, 2024
Downgrades: Neutral
Price Target: $24 → $6
Current: $3.83
Upside: +56.66%
Aug 8, 2024
Upgrades: Buy
Price Target: $13 → $15
Current: $2.23
Upside: +572.65%
Jul 16, 2024
Maintains: Buy
Price Target: $48 → $55
Current: $92.71
Upside: -40.68%
Dec 29, 2022
Maintains: Underperform
Price Target: $5 → $6
Current: $31.51
Upside: -80.96%